Chugai team describes bispecific GPC3 antibody's efficacy

A study published Wednesday in Science Translational Medicine described a novel bispecific antibody that overcomes the "on-target, off-tumor" effects plaguing current cancer immunotherapies utilizing bispecific T-cell redirecting antibodies (TRAB).

While the efficacy of current TRAB therapies is hindered by the use of antigens also expressed by non-tumor tissue, researchers from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) and others identified a novel, solid tumor-specific antigen, glypican 3 (GPC3). The group described ERY974, a bispecific antibody against GPC3 and CD3, and used in vivo mouse and cynomolgus monkey studies to show its efficacy, particularly against tumors lacking neoantigens, and low toxicity...